Up Next
-
8m 14sPart 1 | Session 5 TINTIN: Combination DCB and Bare Metal Stents In PAD: 4 Year Outcomes
-
7m 13sPart 1 | Session 6 POPCORN Registry: DCB Treatment for Peripheral Artery Disease
-
3m 49sPart 1 | Session 7 MOTIV Bioresorbable Scaffold in BTK Lesions
-
6m 6sPart 1 | Session 8 Improving Clinical Outcomes in Infrapopliteal Lesions With Cre8™ BTK
-
8m 56sPart 1 | Session 9 LIFE-BTK: Esprit BTK System in Narrowed Infrapopliteal Lesions
-
5m 2sPart 1 | Session 1 AVPAS: Lutonix AV Post-Approval Study
-
5m 18sPart 1 | Session 2 The ELEGANCE Registry: Ranger DCB In Under-Represented Groups
-
4m 51sPart 1 | Session 3 RANGER II SFA: 3 Year Patency and 4 Year Clinical Safety
About the episode
LINC 23 - Join us as we delve into the findings of the IN.PACT AV Access study with Dr Matteo Tozzi (University of Insurbia, IT).
Sponsored by Medtronic, the IN.PACT AV Access study aimed to compare the efficacy of the IN.PACT AV™ drug-coated balloon with standard percutaneous transluminal angioplasty in patients with de novo or non-stented lesions of the arteriovenous fistula (AVF). A total of 330 patients were enrolled in this trial.
Questions:
- Please remind us of the reasoning behind the IN.PACT AV ACCESS Trial.
- What are the study design and patient cohort?
- What are the key findings revealed at LINC 23?
- Are there any patient cohorts that could benefit more from the use of this DCB?
- How should these findings impact practice?
- What are the next steps?
Recorded remotely from Varese, 2023.
Editor: Jordan Rance
Video Specialist: Dan Brent
Overview
Short, accessible Expert Interviews will be available with select faculty focusing on the results, applicability, and impact on future research.
Comments